Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma
Public ClinicalTrials.gov record NCT01861340. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Pilot Study of Lenalidomide and Dexamethasone in Combination With MEDI-551 in Previously Untreated Multiple Myeloma.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This research study is being done to see if combining the investigational chemotherapy drug, MEDI-551 with the known anti-myeloma drugs, Lenalidomide and Dexamethasone will reduce your myeloma cancer stem cells.
Study identification
- NCT ID
- NCT01861340
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Early Phase 1
- Enrollment
- 20 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 100 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2014
- Primary completion
- Mar 31, 2016
- Completion
- Jun 30, 2016
- Last update posted
- Sep 9, 2018
2014 – 2016
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Sidney Kimmel Comprehensive Cancer Center | Baltimore | Maryland | 21287 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Myeloma trials
Other public records listing Myeloma. Sorted by last update posted; newest first. Not a recommendation.
- NCT07714044: Rutgers University Study of the Genetics of Blood Cancers Not yet recruiting
- NCT07052916: A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties Recruiting
- NCT00871013: Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy Active, not recruiting
- NCT03633955: Pilot Imaging Study of Leukemia Recruiting
- NCT03500445: Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma Active, not recruiting
- NCT04680468: Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01861340, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 9, 2018 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01861340 live on ClinicalTrials.gov.